An air ambulance trauma trial tested whether cold-stored low titer O positive whole blood outperformed standard component therapy, and the results challenged a lot of assumptions. The episode breaks down the physiology, the SWiFT study data, and why whole blood may still have a role in longer or more remote prehospital settings.

This episode explores a new mechanistic approach to treating schizophrenia with xanomeline-trospium, which targets central muscarinic receptors to reduce psychosis without directly blocking dopamine. It also breaks down the EMERGENT trial results, including efficacy, gastrointestinal side effects, and the practical limits of this emerging therapy.

Show Notes

• Efficacy and safety of the muscarinic receptor agonist KarXT ... - PubMed: https://pubmed.ncbi.nlm.nih.gov/38104575/
• Efficacy and Safety of Xanomeline-Trospium Chloride in ...: https://pubmed.ncbi.nlm.nih.gov/38691387/

We break down the FIND-CKD trial and what it means for people with non-diabetic chronic kidney disease and proteinuria, focusing on finerenone’s impact on eGFR decline, kidney-related outcomes, and why an early dip in kidney function may not be a warning sign.

The episode also covers hyperkalemia risk, practical dose adjustment strategies, and the big question of how finerenone fits alongside ACE inhibitors, ARBs, and SGLT2 inhibitors in modern kidney care.

This episode breaks down the C-TRACT trial, comparing iliac vein stenting with standard care for post-thrombotic syndrome and highlighting the trial’s strong improvements in symptoms and quality of life.

It also weighs the trade-offs: higher bleeding risk, heavier antithrombotic therapy, and the unresolved questions around long-term stent durability.

A critical care discussion of why sodium bicarbonate often looks helpful on the blood gas but fails to improve outcomes in vasopressor-dependent metabolic acidosis. The episode breaks down the SODa BIC trial, the surrogate endpoint trap, and when bicarbonate may still have a role in select ICU patients.

We break down the EVERDAC trial, a multicenter randomized study asking whether critically ill patients with shock really need an immediate arterial line. The episode covers noninferior mortality outcomes, major reductions in catheter-related bleeding, and how this could shift ICU practice toward a more selective, noninvasive approach.

Show Notes

• Deferring Arterial Catheterization in Critically Ill Patients with Shock | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2502136

This episode examines the EARLY TAVR trial and why “asymptomatic” severe aortic stenosis may be misleading, with treadmill testing revealing many patients were not truly symptom-free. It also breaks down the results: fewer unplanned hospitalizations with early intervention, but no clear mortality benefit yet, alongside the procedural risks and shared decision-making implications.

A deep dive into the CLL17 trial and the shift from indefinite BTK inhibition to fixed-duration venetoclax-based therapy. The hosts unpack noninferior progression-free survival, striking MRD clearance, and the trade-offs between continuous treatment and a defined endpoint.

Show Notes

• Fixed-Duration versus Continuous Treatment for Chronic ...: https://www.nejm.org/doi/full/10.1056/NEJMoa2515458

This episode breaks down the APPLAUSE IgAN phase 3 trial of iptacopan in high-risk IgA nephropathy, highlighting meaningful slowing of eGFR decline, lower kidney failure events, and how surrogate proteinuria changes translated into real clinical benefit.

It also examines the trade-off of complement blockade, including the need for careful vaccination and the increased risk of serious infections in patients with severe proteinuria.

Show Notes

• Iptacopan Slows Kidney Function Decline in IgA Nephropathy: https://www.renalandurologynews.com/news/iga-neprhopathy-iptacopan-kidney-function-treatment-risk/
• Iptacopan for IgA Nephropathy in: https://www.kidneynews.org/view/journals/kidney-news/18/5/article-p29_19.xml

This episode breaks down the CREST 2 trials and the tough decision facing patients with severe asymptomatic carotid stenosis: accept the upfront risk of stenting or surgery, or rely on intensive medical therapy alone. The hosts examine short-term procedural harms, four-year outcomes, and why modern medication has changed the standard of care.

Show Notes

• Medical Management and Revascularization for ...: https://www.nejm.org/doi/abs/10.1056/NEJMoa2508800